SAB Biotherapeutics (NASDAQ:SABS) Coverage Initiated by Analysts at Oppenheimer

Equities researchers at Oppenheimer assumed coverage on shares of SAB Biotherapeutics (NASDAQ:SABS) in a report issued on Wednesday, Benzinga reports. The brokerage set an “outperform” rating and a $12.00 price target on the stock. Oppenheimer’s price target indicates a potential upside of 376.85% from the stock’s current price.

Several other equities research analysts have also weighed in on SABS. Chardan Capital restated a “buy” rating and set a $25.00 price target on shares of SAB Biotherapeutics in a research report on Monday, August 12th. Brookline Capital Management initiated coverage on shares of SAB Biotherapeutics in a research report on Friday, June 7th. They issued a “buy” rating and a $8.00 target price on the stock. Finally, HC Wainwright reissued a “buy” rating and set a $6.00 price target on shares of SAB Biotherapeutics in a research report on Monday, August 12th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $12.75.

SAB Biotherapeutics Stock Down 10.4 %

Shares of NASDAQ SABS opened at $2.52 on Wednesday. The firm has a fifty day simple moving average of $2.76 and a two-hundred day simple moving average of $3.72. SAB Biotherapeutics has a 12 month low of $2.16 and a 12 month high of $10.50. The company has a debt-to-equity ratio of 0.06, a quick ratio of 5.65 and a current ratio of 5.65.

SAB Biotherapeutics (NASDAQ:SABS) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.79) EPS for the quarter, topping the consensus estimate of ($1.13) by $0.34. The business had revenue of $0.26 million during the quarter. SAB Biotherapeutics had a negative net margin of 1,531.26% and a negative return on equity of 109.90%. Equities research analysts expect that SAB Biotherapeutics will post -4.08 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of SABS. RTW Investments LP purchased a new stake in SAB Biotherapeutics during the 4th quarter valued at $6,310,000. BVF Inc. IL purchased a new stake in shares of SAB Biotherapeutics during the fourth quarter valued at $6,310,000. Commodore Capital LP bought a new stake in SAB Biotherapeutics in the 4th quarter worth about $1,259,000. Finally, First PREMIER Bank purchased a new position in SAB Biotherapeutics in the 2nd quarter worth about $60,000. 7.82% of the stock is owned by hedge funds and other institutional investors.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.